You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

GLUCAGON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GLUCAGON?
  • What are the global sales for GLUCAGON?
  • What is Average Wholesale Price for GLUCAGON?
Summary for GLUCAGON
Drug patent expirations by year for GLUCAGON
Drug Prices for GLUCAGON

See drug prices for GLUCAGON

Recent Clinical Trials for GLUCAGON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pichamol Jirapinyo, MD, MPHPhase 4
National Center for Advancing Translational Sciences (NCATS)Early Phase 1
Ain Shams UniversityN/A

See all GLUCAGON clinical trials

Medical Subject Heading (MeSH) Categories for GLUCAGON

US Patents and Regulatory Information for GLUCAGON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amphastar Pharms Inc GLUCAGON glucagon INJECTABLE;INJECTION 208086-001 Dec 28, 2020 RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly GLUCAGON glucagon hydrochloride INJECTABLE;INJECTION 012122-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly GLUCAGON glucagon hydrochloride INJECTABLE;INJECTION 012122-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lilly GLUCAGON glucagon INJECTABLE;INJECTION 020928-001 Sep 11, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa GLUCAGON glucagon hydrochloride POWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 201849-002 Sep 19, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for GLUCAGON

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Tetris Pharma B.V Ogluo glucagon EMEA/H/C/005391
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Authorised no no no 2021-02-11
Eli Lilly Nederland B.V. Baqsimi glucagon EMEA/H/C/003848
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Authorised no no no 2019-12-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.